(Received for publication 5 March 1974) There is general agreement that the mature cells of the blood of mammals arise from a pluripotent hemopoietic stem cell (1) (2) (3) (4) . This cell is defined by ability to form spleen colonies after injection into lethally irradiated mice (5) and is thus called a spleen colony-forming unit or CFU-s. Colonies of myeloid cells can be formed in vitro (6, 3) and the cells which give rise to these colonies (CFU-c) differ in many properties from the CFU-s. The CFU-c appear to be slightly denser (8, 9) , have a higher sedimentation rate, (8) and have a larger proportion of cells in S phase of the cell cycle than CFU-s (10, 11) . It seems reasonable to consider the CFU-c as a different, more differentiated cell than the CFU-s which may be considered the earliest known hemopoietic cell. The cell responsive to the inductive factors which either cause or allow expression along a given differentiative pathway is called the progenitor cell. It is not clear how far removed from the stem cell the progenitor cell is in differentiative steps or at what stage the progenitor becomes a determined cell. Once the progenitor cell has begun to differentiate along a given pathway toward an end cell the intermediate cell types may be considered precursor cells of that end cell.
An antigen shared with CFU-s was found in mouse brain making it possible to produce an anti-CFU-s (or an antistem cell) antibody (12) . This brainassociated stem cell specificity was shown to be different from brain-associated 0 (13) and brain-associated erythroid specificities (14) . Using rabbit or goat antibrain antisera it has been possible to eliminate CFU-s from bone marrow or spleen. In this paper, we have used antistem cell antiserum to show that the progenitor cell which is responsible for in vitro myeloid colonies does not share the brain-associated stem cell antigen with the pluripotent cell responsible for spleen colonies. Thus, a clear antigenic difference can be demonstrated to have occurred in early hemopoietic differentiation.
Materials and Methods
Animals.--BDF1 (C57BL/6 X DBA/2) mice were used for all but one of the experiments. These mice were bred at Purdue using stocks obtained from Jackson Laboratories, Bar Harbor, Maine. Animals were maintained five to a cage with driking water containing 11 ppm chlorine at pH 2.8 (15) . CBA mice were used in the double cell transfer experiment which was carried out at Rijswijk. These animals are also maintained on low pH, high chlorine water.
X Irradiation.--The conditions for X irradiation at Purdue were as described in (12) and for Rijswijk as in (16) . 
CFU-c:
Myeloid precursor cells were assayed essentially by the method described by Metcalf and Moore (17) . 1 X 105 bone marrow cells were suspended in Dulbecco's medium with 0.3% agar. 10% colony-stimulating factor (CSF) extracted from mouse uteri according to the method of Bradley (18) was added and 1 ml aliquots were distributed in 35 mm Falcon dishes and incubated at 37C with 10% CO2 in 100% humidity. Colonies were counted at day 7. The CSF levels used were those which allowed maximal expression of CFU-c. 1
Antisera: Antistem cell antiserum was produced as described previously (12, 13) . The batch used in the experiments reported here was from a goat which had received two injections of CBA brain emulsified in complete Freund's adjuvant (13) . The standard antiserum was absorbed with mouse erythrocyte and liver (19) . In most experiments the serum was also absorbed with thymus cells. The rabbit antigoat gamma globulin was kindly provided by Dr. R. M. E. Parkhouse, Medical Research Council Laboratory, Mill Hill, London.
RESULTS

Effect of Antimouse Brain Antiserum on In Vivo and In Vitro Colony
Formation.--To determine the effects of the antistem cell antiserum on in vitro colony formation (CFU-c) and in vivo colony formation (CFU-s), bone marrow cells from BDF1 mice were treated with dilutions of goat antimouse brain antiserum absorbed with red cells, liver, and thymus as described in Materials and Methods. After this treatment, varying concentrations of cells were injected into lethally irradiated BDF1 recipients to determine the numbers of surviving CFU-s or cultured in vitro with CSF to determine the number of surviving CFU-c. In vitro colonies were counted at day 7 and in vivo colonies at day 10. The results of three such experiments are presented in Table I .
It can be seen that there was a 75-85 % reduction of CFU-s but that the number of CFU-c was not significantly reduced. This result was also obtained with three separate batches of rabbit anti-CBA brain and another batch of goat anti-CBA serum.
Evidence that the Lack oJ Reduction of CFU-c is not due to Inefficient In Vitro Cytotoxicity of CFU-c.--
The results in the previous section can be interpreted as showing that the CFU-c does not share an antigen with CFU-s. However, it is necessary to show that the difference is not due to the fact that there is a differential ability of cells to be lysed in vivo and in vitro. For example, both CFU-c and CFU-s could share the stem cell antigen and both could react with the antistem cell antibody but treatment with complement in vitro may not cause the cells to lyse. When the cells with their reacted antibody are injected into the mouse, conditions in vivo could allow lysis. The cell being tested for in vitro colony formation would not be subjected to this in vivo action and would thus express itself as a colony-forming unit even through it shared the antigen. Indeed, CFU-s which have been reacted with antistem cell antibody in vitro in the absence of complement are inhibited from forming colonies in vivo. Presumably, this is due to some action of the recipient on the cellantibody complex in vivo. Several experiments were carried out to decide between these alternatives.
Effect of Antiglobulin Treatment.--Bone marrow cells were treated with the goat antibrain antiserum for 30 min in the cold, washed, and then reacted with a 1/10 dilution of rabbit antigoat gamma globulin. After a further 30 min in the cold the cells were washed and treated with guinea pig complement for 1 h at 37°C and then tested for ability to form in vitro colonies. Treatment with the antiglobulin antiserum did not cause any reduction in CFU-c expression.
The Eject of In Vivo Passage of In Vitro-Treated CelIs.--Bone marrow cells were treated with complement alone (Group A) or with antibrain plus complement (Group B). l0 G of these cells were then injected into lethally irradiated mice. One group of irradiated mice received no bone marrow cells (Group C). 24 h later, the spleens of these irradiated mice were harvested, cultured in vitro to determine the number of CFU-c or injected into another set of irradiated mice to determine the number of surviving CFU-s. Thus, if the host mouse were contributing to the lysis of the antistem cell antibody-treated cells, there should be a reduction in the number o[ colony-forming units in the spleens of these adoptive hosts when assayed for CFU-c. If colonies were obtained from these irradiated hosts, i.e., if there were no reduction by passage through the animal, this would argue against inefficient lysis in vitro being responsible for lack of reduction of CFU-c seen after in vitro treatment.
The results of this last experiment are presented in Table II . It can be seen that there was no reduction in the number of in vitro colonies formed after passage of the cells through the irradiated host.
DISCUSSION
The experiments in this paper were designed to answer the question of whether the progenitor cell which is responsible for in vitro colonies shares the brain-associated stem cell antigen with the cell responsible for spleen colonies. This was accomplished by determining if in vitro colonies were prevented from being formed after reaction of bone marrow cells with antibrain antiserum and complement. Antibrain sera contain antibodies which prevent the formation of in vivo colonies (12), i.e., antistem cell antibodies. The experiments reported here show that treatment of bone marrow cells with such an antiserum and complement does not prevent in vitro colonies from forming. It can be seen in Table I that while spleen colony formation is essentially abolished, in vitro colony formation is essentially unaffected. Furthermore, the same result was obtained with antisera absorbed with thymus and thus devoid of the brain-associated 0 specificity (13) .
The failure to impair expression of in vitro colonies after anti-brain antiserum treatment was shown not to be due to inefficient in vitro cytotoxicity. Since bone marrow cells which were reacted with antibody in vitro, passaged through an irradiated animal and recovered still were able to form in vitro colonies (Table II) .
There are a number of physical and physiological differences between CFU-c and CFU-s (8-11), the most striking being that the CFU-s is pluripotent but the CFU-c is a determined cell. The CFU-c is responsive to inductive influences and microenvironments which the stem cell is not. The data in this paper show that along with these functional changes, there is an antigenic change which has also occurred in the differentiation from stem cell to progenitor cell.
We have, as of yet, no marker antigen for the progenitor cell as we do for the stem cell (12) , and for several later stages of differentiation of the progenitor cell. The cells which are derived from the lymphoid progenitor and which are determined to become T lymphocytes (20) under thymic influence will express a variety of antigens at different stages of differentiation. An example of these differentiation antigens (21) on the lymphocyte in the thymus (To cell) is the expression of TL and 0. After further differentiation and the export to the peripheral lymphoid tissue, these cells become T1 and T2 (22) thymic-derived lymphocytes and no longer express TL while still expressing 0. Similarly, we have demonstrated that B-lymphocyte precursor cells in the bone marrow and B cells in the peripheral lymphoid compartments which are responsive to the same antigen in thymic-dependent or in thymic-independent forms have characteristic surface antigens associated with their stage of development3
It is probable that antigenic differences are associated with all or most stages in hemopoietic differentiation. If this is the case, as we identify the antigens we will have powerful tools for the study of hemopoiesis, both normal and leukemic, since we will be able to identify or eliminate cells at specific stages of differentiation. We are currently determining if the erythroid and lymphoid progenitor cells also lack the stem cell antigen and are attempting to identify early lymphoid precursor cells by unique surface antigens.
SUMMARY
Bone marrow contains pluripotent stem cells which give rise to colonies when injected into irradiated syngenic hosts as well as more differentiated progenitor cells of the myeloid cell which are able to form colonies in vitro. Antisera against brain is known to contain antistem cell antibody. The present experiments were designed to determine if the myeloid progenitor cell still expresses the stem cell antigen.
Bone marrow cells were treated with antibrain antiserum plus complement and then survival of stem cells was determined by injection into irradiated hosts. Survival of myeloid progenitor cells was determined by culturing the cells in vitro. It was found that stem cells were eliminated by the antiserum but that myeloid progenitors were not. Inefficient in vitro lysis was ruled out as the reason for this difference since in vitro colonies were not reduced when the cells were treated with anti-immunoglobulin or after passage through an irradiated host. In the differentiation from stem cell to myeloid progenitor there is an associated surface antigen change.
